nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABCG2—Sulfasalazine—ankylosing spondylitis	0.183	0.277	CbGbCtD
Afatinib—ABCG2—Dexamethasone—ankylosing spondylitis	0.0912	0.138	CbGbCtD
Afatinib—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0869	0.132	CbGbCtD
Afatinib—ABCG2—Methotrexate—ankylosing spondylitis	0.0733	0.111	CbGbCtD
Afatinib—ABCB1—Betamethasone—ankylosing spondylitis	0.0565	0.0858	CbGbCtD
Afatinib—ABCB1—Prednisolone—ankylosing spondylitis	0.0558	0.0847	CbGbCtD
Afatinib—ABCB1—Prednisone—ankylosing spondylitis	0.0527	0.08	CbGbCtD
Afatinib—ABCB1—Dexamethasone—ankylosing spondylitis	0.0329	0.0499	CbGbCtD
Afatinib—ABCB1—Methotrexate—ankylosing spondylitis	0.0264	0.0401	CbGbCtD
Afatinib—Paronychia—Methotrexate—ankylosing spondylitis	0.00545	0.0405	CcSEcCtD
Afatinib—Dermatitis acneiform—Triamcinolone—ankylosing spondylitis	0.00419	0.0311	CcSEcCtD
Afatinib—Dermatitis acneiform—Methylprednisolone—ankylosing spondylitis	0.00418	0.0311	CcSEcCtD
Afatinib—Pulmonary toxicity—Methotrexate—ankylosing spondylitis	0.00416	0.0309	CcSEcCtD
Afatinib—Dermatitis acneiform—Dexamethasone—ankylosing spondylitis	0.0038	0.0282	CcSEcCtD
Afatinib—Dermatitis acneiform—Betamethasone—ankylosing spondylitis	0.0038	0.0282	CcSEcCtD
Afatinib—Blood potassium decreased—Methylprednisolone—ankylosing spondylitis	0.00375	0.0279	CcSEcCtD
Afatinib—Conjunctival hyperaemia—Prednisolone—ankylosing spondylitis	0.00354	0.0263	CcSEcCtD
Afatinib—Dermatitis acneiform—Prednisone—ankylosing spondylitis	0.00331	0.0246	CcSEcCtD
Afatinib—Blood potassium decreased—Prednisone—ankylosing spondylitis	0.00297	0.0221	CcSEcCtD
Afatinib—Conjunctival hyperaemia—Dexamethasone—ankylosing spondylitis	0.00295	0.0219	CcSEcCtD
Afatinib—Conjunctival hyperaemia—Betamethasone—ankylosing spondylitis	0.00295	0.0219	CcSEcCtD
Afatinib—Keratitis—Prednisolone—ankylosing spondylitis	0.0024	0.0178	CcSEcCtD
Afatinib—Keratitis—Betamethasone—ankylosing spondylitis	0.002	0.0149	CcSEcCtD
Afatinib—Keratitis—Dexamethasone—ankylosing spondylitis	0.002	0.0149	CcSEcCtD
Afatinib—Mucosal inflammation—Methotrexate—ankylosing spondylitis	0.00171	0.0127	CcSEcCtD
Afatinib—ERBB2—Exemestane—Methylprednisolone—ankylosing spondylitis	0.00165	0.12	CbGdCrCtD
Afatinib—ERBB2—Exemestane—Prednisone—ankylosing spondylitis	0.00151	0.109	CbGdCrCtD
Afatinib—ERBB2—Exemestane—Prednisolone—ankylosing spondylitis	0.00147	0.106	CbGdCrCtD
Afatinib—Interstitial lung disease—Methotrexate—ankylosing spondylitis	0.00133	0.00992	CcSEcCtD
Afatinib—Dry eye—Betamethasone—ankylosing spondylitis	0.0012	0.00891	CcSEcCtD
Afatinib—Dry eye—Dexamethasone—ankylosing spondylitis	0.0012	0.00891	CcSEcCtD
Afatinib—Dry skin—Prednisolone—ankylosing spondylitis	0.00104	0.00769	CcSEcCtD
Afatinib—Sepsis—Prednisone—ankylosing spondylitis	0.000981	0.00729	CcSEcCtD
Afatinib—ABL1—Pathogenic Escherichia coli infection—TLR4—ankylosing spondylitis	0.000976	0.00505	CbGpPWpGaD
Afatinib—ERBB2—B Cell Activation—CD79A—ankylosing spondylitis	0.000954	0.00493	CbGpPWpGaD
Afatinib—ERBB4—B Cell Activation—CD79A—ankylosing spondylitis	0.000939	0.00486	CbGpPWpGaD
Afatinib—ERBB2—Immune System—KIR3DL1—ankylosing spondylitis	0.000927	0.00479	CbGpPWpGaD
Afatinib—Cystitis noninfective—Methotrexate—ankylosing spondylitis	0.000923	0.00686	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Methylprednisolone—ankylosing spondylitis	0.000914	0.00679	CcSEcCtD
Afatinib—ERBB4—Immune System—KIR3DL1—ankylosing spondylitis	0.000913	0.00472	CbGpPWpGaD
Afatinib—Cystitis—Methotrexate—ankylosing spondylitis	0.000912	0.00678	CcSEcCtD
Afatinib—IRAK1—Signaling by Interleukins—IL1A—ankylosing spondylitis	0.000907	0.00469	CbGpPWpGaD
Afatinib—LCK—TCR signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000905	0.00468	CbGpPWpGaD
Afatinib—BLK—B Cell Activation—CD79A—ankylosing spondylitis	0.000904	0.00467	CbGpPWpGaD
Afatinib—ERBB2—Triamcinolone—Methylprednisolone—ankylosing spondylitis	0.000899	0.0651	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Betamethasone—ankylosing spondylitis	0.000884	0.0641	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Dexamethasone—ankylosing spondylitis	0.000884	0.0641	CbGdCrCtD
Afatinib—BLK—Immune System—KIR3DL1—ankylosing spondylitis	0.000878	0.00454	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000878	0.00454	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000865	0.00447	CbGpPWpGaD
Afatinib—Dry skin—Dexamethasone—ankylosing spondylitis	0.000864	0.00642	CcSEcCtD
Afatinib—Dry skin—Betamethasone—ankylosing spondylitis	0.000864	0.00642	CcSEcCtD
Afatinib—Hypokalaemia—Dexamethasone—ankylosing spondylitis	0.000858	0.00637	CcSEcCtD
Afatinib—Hypokalaemia—Betamethasone—ankylosing spondylitis	0.000858	0.00637	CcSEcCtD
Afatinib—Bladder pain—Methotrexate—ankylosing spondylitis	0.000854	0.00635	CcSEcCtD
Afatinib—Mouth ulceration—Methotrexate—ankylosing spondylitis	0.000854	0.00635	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Methylprednisolone—ankylosing spondylitis	0.000853	0.0618	CbGdCrCtD
Afatinib—Conjunctivitis—Prednisolone—ankylosing spondylitis	0.000846	0.00629	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Betamethasone—ankylosing spondylitis	0.00084	0.0608	CbGdCrCtD
Afatinib—ERBB2—Desoximetasone—Dexamethasone—ankylosing spondylitis	0.00084	0.0608	CbGdCrCtD
Afatinib—ERBB2—Innate Immune System—CARD9—ankylosing spondylitis	0.000836	0.00432	CbGpPWpGaD
Afatinib—Upper respiratory tract infection—Triamcinolone—ankylosing spondylitis	0.000834	0.0062	CcSEcCtD
Afatinib—BLK—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000832	0.0043	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—CARD9—ankylosing spondylitis	0.000823	0.00426	CbGpPWpGaD
Afatinib—ERBB2—Desoximetasone—Triamcinolone—ankylosing spondylitis	0.000821	0.0595	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Prednisone—ankylosing spondylitis	0.00082	0.0594	CbGdCrCtD
Afatinib—Sepsis—Methotrexate—ankylosing spondylitis	0.00082	0.00609	CcSEcCtD
Afatinib—LCK—IL12-mediated signaling events—HLA-A—ankylosing spondylitis	0.000819	0.00424	CbGpPWpGaD
Afatinib—IRAK1—MyD88:Mal cascade initiated on plasma membrane—TLR4—ankylosing spondylitis	0.000812	0.0042	CbGpPWpGaD
Afatinib—LCK—Signaling by Interleukins—IL1RN—ankylosing spondylitis	0.000812	0.0042	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.000801	0.00414	CbGpPWpGaD
Afatinib—ERBB2—Triamcinolone—Prednisolone—ankylosing spondylitis	0.0008	0.058	CbGdCrCtD
Afatinib—ERBB2—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000799	0.00413	CbGpPWpGaD
Afatinib—Infestation—Methylprednisolone—ankylosing spondylitis	0.000798	0.00593	CcSEcCtD
Afatinib—Infestation NOS—Methylprednisolone—ankylosing spondylitis	0.000798	0.00593	CcSEcCtD
Afatinib—ERBB4—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000787	0.00407	CbGpPWpGaD
Afatinib—IRAK1—MyD88-independent cascade—TLR4—ankylosing spondylitis	0.000779	0.00403	CbGpPWpGaD
Afatinib—ERBB2—Desoximetasone—Prednisone—ankylosing spondylitis	0.000779	0.0564	CbGdCrCtD
Afatinib—Conjunctivitis—Triamcinolone—ankylosing spondylitis	0.000778	0.00578	CcSEcCtD
Afatinib—LCK—B Cell Receptor Signaling Pathway—CD79A—ankylosing spondylitis	0.000777	0.00402	CbGpPWpGaD
Afatinib—PHKG2—Disease—B3GNT2—ankylosing spondylitis	0.000771	0.00399	CbGpPWpGaD
Afatinib—IRAK1—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	0.000761	0.00393	CbGpPWpGaD
Afatinib—ERBB2—Desoximetasone—Prednisolone—ankylosing spondylitis	0.00076	0.0551	CbGdCrCtD
Afatinib—Epistaxis—Triamcinolone—ankylosing spondylitis	0.000755	0.00561	CcSEcCtD
Afatinib—Dry skin—Prednisone—ankylosing spondylitis	0.000752	0.00559	CcSEcCtD
Afatinib—Hypokalaemia—Prednisone—ankylosing spondylitis	0.000747	0.00555	CcSEcCtD
Afatinib—EGFR—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000739	0.00382	CbGpPWpGaD
Afatinib—Weight decreased—Betamethasone—ankylosing spondylitis	0.000737	0.00548	CcSEcCtD
Afatinib—Weight decreased—Dexamethasone—ankylosing spondylitis	0.000737	0.00548	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Prednisone—ankylosing spondylitis	0.000724	0.00538	CcSEcCtD
Afatinib—LCK—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000712	0.00368	CbGpPWpGaD
Afatinib—Conjunctivitis—Betamethasone—ankylosing spondylitis	0.000706	0.00525	CcSEcCtD
Afatinib—Conjunctivitis—Dexamethasone—ankylosing spondylitis	0.000706	0.00525	CcSEcCtD
Afatinib—Connective tissue disorder—Methylprednisolone—ankylosing spondylitis	0.000704	0.00523	CcSEcCtD
Afatinib—IRAK1—Activated TLR4 signalling—TLR4—ankylosing spondylitis	0.000701	0.00362	CbGpPWpGaD
Afatinib—ABCG2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000691	0.00357	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.000677	0.0035	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KIR3DL1—ankylosing spondylitis	0.00067	0.00347	CbGpPWpGaD
Afatinib—Eye disorder—Methylprednisolone—ankylosing spondylitis	0.00067	0.00498	CcSEcCtD
Afatinib—IRAK1—Toll Like Receptor 4 (TLR4) Cascade—TLR4—ankylosing spondylitis	0.000659	0.00341	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000653	0.00338	CbGpPWpGaD
Afatinib—ERBB2—Disease—ANTXR2—ankylosing spondylitis	0.000649	0.00335	CbGpPWpGaD
Afatinib—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.000646	0.0048	CcSEcCtD
Afatinib—PHKG2—Metabolism—B3GNT2—ankylosing spondylitis	0.000646	0.00334	CbGpPWpGaD
Afatinib—Weight decreased—Prednisone—ankylosing spondylitis	0.000642	0.00477	CcSEcCtD
Afatinib—ERBB4—Disease—ANTXR2—ankylosing spondylitis	0.000639	0.0033	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000629	0.00325	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	0.000629	0.00325	CbGpPWpGaD
Afatinib—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.000628	0.00467	CcSEcCtD
Afatinib—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000624	0.00464	CcSEcCtD
Afatinib—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.000612	0.00455	CcSEcCtD
Afatinib—Eye disorder—Dexamethasone—ankylosing spondylitis	0.000609	0.00453	CcSEcCtD
Afatinib—Eye disorder—Betamethasone—ankylosing spondylitis	0.000609	0.00453	CcSEcCtD
Afatinib—Back pain—Triamcinolone—ankylosing spondylitis	0.000605	0.0045	CcSEcCtD
Afatinib—IRAK1—Innate Immune System—CARD9—ankylosing spondylitis	0.000604	0.00313	CbGpPWpGaD
Afatinib—IRAK1—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.000594	0.00307	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000588	0.00304	CbGpPWpGaD
Afatinib—IRAK1—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	0.000587	0.00304	CbGpPWpGaD
Afatinib—LCK—Signaling by Interleukins—IL1A—ankylosing spondylitis	0.000584	0.00302	CbGpPWpGaD
Afatinib—Alopecia—Betamethasone—ankylosing spondylitis	0.000576	0.00428	CcSEcCtD
Afatinib—Alopecia—Dexamethasone—ankylosing spondylitis	0.000576	0.00428	CcSEcCtD
Afatinib—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	0.000575	0.00297	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.000565	0.00292	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL1R2—ankylosing spondylitis	0.000562	0.0029	CbGpPWpGaD
Afatinib—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.000558	0.00415	CcSEcCtD
Afatinib—ERBB4—Immune System—IL1R2—ankylosing spondylitis	0.000553	0.00286	CbGpPWpGaD
Afatinib—Upper respiratory tract infection—Methotrexate—ankylosing spondylitis	0.000551	0.00409	CcSEcCtD
Afatinib—Cough—Triamcinolone—ankylosing spondylitis	0.000546	0.00406	CcSEcCtD
Afatinib—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	0.000534	0.00276	CbGpPWpGaD
Afatinib—ERBB2—Immune System—ERAP1—ankylosing spondylitis	0.000532	0.00275	CbGpPWpGaD
Afatinib—BLK—Immune System—IL1R2—ankylosing spondylitis	0.000532	0.00275	CbGpPWpGaD
Afatinib—Pneumonia—Methotrexate—ankylosing spondylitis	0.000532	0.00395	CcSEcCtD
Afatinib—Eye disorder—Prednisone—ankylosing spondylitis	0.000531	0.00394	CcSEcCtD
Afatinib—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000528	0.00393	CcSEcCtD
Afatinib—Infestation—Methotrexate—ankylosing spondylitis	0.000528	0.00393	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000528	0.00392	CcSEcCtD
Afatinib—ERBB2—Innate Immune System—HLA-C—ankylosing spondylitis	0.000525	0.00271	CbGpPWpGaD
Afatinib—ABL1—Immune System—KIR3DL1—ankylosing spondylitis	0.000524	0.00271	CbGpPWpGaD
Afatinib—ERBB4—Immune System—ERAP1—ankylosing spondylitis	0.000524	0.00271	CbGpPWpGaD
Afatinib—Renal failure—Methotrexate—ankylosing spondylitis	0.000519	0.00386	CcSEcCtD
Afatinib—ERBB4—Innate Immune System—HLA-C—ankylosing spondylitis	0.000517	0.00267	CbGpPWpGaD
Afatinib—Stomatitis—Methotrexate—ankylosing spondylitis	0.000515	0.00383	CcSEcCtD
Afatinib—Conjunctivitis—Methotrexate—ankylosing spondylitis	0.000514	0.00382	CcSEcCtD
Afatinib—Infection—Triamcinolone—ankylosing spondylitis	0.000507	0.00377	CcSEcCtD
Afatinib—Infection—Methylprednisolone—ankylosing spondylitis	0.000506	0.00376	CcSEcCtD
Afatinib—BLK—Immune System—ERAP1—ankylosing spondylitis	0.000504	0.00261	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000504	0.00261	CbGpPWpGaD
Afatinib—Insomnia—Prednisolone—ankylosing spondylitis	0.000502	0.00373	CcSEcCtD
Afatinib—Alopecia—Prednisone—ankylosing spondylitis	0.000502	0.00373	CcSEcCtD
Afatinib—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.0005	0.00371	CcSEcCtD
Afatinib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000499	0.00371	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—ankylosing spondylitis	0.000498	0.0037	CcSEcCtD
Afatinib—Mental disorder—Prednisone—ankylosing spondylitis	0.000497	0.0037	CcSEcCtD
Afatinib—ERBB4—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000497	0.00257	CbGpPWpGaD
Afatinib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000495	0.00368	CcSEcCtD
Afatinib—Malnutrition—Prednisone—ankylosing spondylitis	0.000494	0.00367	CcSEcCtD
Afatinib—ERBB2—Immune System—CARD9—ankylosing spondylitis	0.000487	0.00252	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CARD9—ankylosing spondylitis	0.00048	0.00248	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000478	0.00247	CbGpPWpGaD
Afatinib—ABL1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—ankylosing spondylitis	0.000475	0.00245	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CARD9—ankylosing spondylitis	0.000473	0.00245	CbGpPWpGaD
Afatinib—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000469	0.00348	CcSEcCtD
Afatinib—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000465	0.00346	CcSEcCtD
Afatinib—Insomnia—Triamcinolone—ankylosing spondylitis	0.000462	0.00343	CcSEcCtD
Afatinib—BLK—Immune System—CARD9—ankylosing spondylitis	0.000461	0.00239	CbGpPWpGaD
Afatinib—EGFR—B Cell Activation—CD79A—ankylosing spondylitis	0.000461	0.00238	CbGpPWpGaD
Afatinib—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000461	0.00342	CcSEcCtD
Afatinib—Infection—Betamethasone—ankylosing spondylitis	0.00046	0.00342	CcSEcCtD
Afatinib—Infection—Dexamethasone—ankylosing spondylitis	0.00046	0.00342	CcSEcCtD
Afatinib—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000455	0.00338	CcSEcCtD
Afatinib—EGFR—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	0.000454	0.00235	CbGpPWpGaD
Afatinib—EGFR—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	0.000454	0.00235	CbGpPWpGaD
Afatinib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000454	0.00338	CcSEcCtD
Afatinib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000454	0.00338	CcSEcCtD
Afatinib—EGFR—Spinal Cord Injury—TLR4—ankylosing spondylitis	0.000453	0.00234	CbGpPWpGaD
Afatinib—LCK—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	0.000453	0.00234	CbGpPWpGaD
Afatinib—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000449	0.00334	CcSEcCtD
Afatinib—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000448	0.00333	CcSEcCtD
Afatinib—EGFR—Immune System—KIR3DL1—ankylosing spondylitis	0.000448	0.00232	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—CD79A—ankylosing spondylitis	0.000444	0.0023	CbGpPWpGaD
Afatinib—Eye disorder—Methotrexate—ankylosing spondylitis	0.000443	0.00329	CcSEcCtD
Afatinib—Fatigue—Triamcinolone—ankylosing spondylitis	0.00044	0.00327	CcSEcCtD
Afatinib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000439	0.00326	CcSEcCtD
Afatinib—LCK—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.000436	0.00226	CbGpPWpGaD
Afatinib—LCK—Immune System—KIR3DL1—ankylosing spondylitis	0.000432	0.00223	CbGpPWpGaD
Afatinib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000428	0.00318	CcSEcCtD
Afatinib—EGFR—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000426	0.0022	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000424	0.00219	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000423	0.00219	CbGpPWpGaD
Afatinib—Alopecia—Methotrexate—ankylosing spondylitis	0.000419	0.00312	CcSEcCtD
Afatinib—Insomnia—Dexamethasone—ankylosing spondylitis	0.000419	0.00311	CcSEcCtD
Afatinib—Insomnia—Betamethasone—ankylosing spondylitis	0.000419	0.00311	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000418	0.0031	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—ankylosing spondylitis	0.000416	0.00309	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—ankylosing spondylitis	0.000413	0.00307	CcSEcCtD
Afatinib—LCK—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000409	0.00211	CbGpPWpGaD
Afatinib—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.000408	0.00303	CcSEcCtD
Afatinib—Dyspepsia—Betamethasone—ankylosing spondylitis	0.000408	0.00303	CcSEcCtD
Afatinib—IRAK1—Immune System—IL1R2—ankylosing spondylitis	0.000406	0.0021	CbGpPWpGaD
Afatinib—Dysgeusia—Methotrexate—ankylosing spondylitis	0.000404	0.00301	CcSEcCtD
Afatinib—EGFR—Innate Immune System—CARD9—ankylosing spondylitis	0.000404	0.00209	CbGpPWpGaD
Afatinib—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000403	0.003	CcSEcCtD
Afatinib—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000403	0.00299	CcSEcCtD
Afatinib—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000403	0.00299	CcSEcCtD
Afatinib—Infection—Prednisone—ankylosing spondylitis	0.000401	0.00298	CcSEcCtD
Afatinib—IRAK1—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.0004	0.00207	CbGpPWpGaD
Afatinib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.0004	0.00297	CcSEcCtD
Afatinib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.0004	0.00297	CcSEcCtD
Afatinib—Back pain—Methotrexate—ankylosing spondylitis	0.000399	0.00297	CcSEcCtD
Afatinib—Fatigue—Dexamethasone—ankylosing spondylitis	0.000399	0.00297	CcSEcCtD
Afatinib—Fatigue—Betamethasone—ankylosing spondylitis	0.000399	0.00297	CcSEcCtD
Afatinib—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000396	0.00294	CcSEcCtD
Afatinib—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	0.000393	0.00203	CbGpPWpGaD
Afatinib—Skin disorder—Prednisone—ankylosing spondylitis	0.000392	0.00291	CcSEcCtD
Afatinib—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000391	0.00202	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	0.000391	0.00202	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CARD9—ankylosing spondylitis	0.000389	0.00201	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000386	0.002	CbGpPWpGaD
Afatinib—IRAK1—Immune System—ERAP1—ankylosing spondylitis	0.000385	0.00199	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000384	0.00199	CbGpPWpGaD
Afatinib—ERBB2—Disease—B3GNT2—ankylosing spondylitis	0.000382	0.00198	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—HLA-C—ankylosing spondylitis	0.00038	0.00196	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000379	0.00196	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000379	0.00196	CbGpPWpGaD
Afatinib—ERBB4—Disease—B3GNT2—ankylosing spondylitis	0.000377	0.00195	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000373	0.00193	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000372	0.00192	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000372	0.00192	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000371	0.00192	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.00037	0.00191	CbGpPWpGaD
Afatinib—Dizziness—Prednisolone—ankylosing spondylitis	0.000367	0.00273	CcSEcCtD
Afatinib—Asthenia—Triamcinolone—ankylosing spondylitis	0.000366	0.00272	CcSEcCtD
Afatinib—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000366	0.00272	CcSEcCtD
Afatinib—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000366	0.00272	CcSEcCtD
Afatinib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000365	0.00272	CcSEcCtD
Afatinib—Insomnia—Prednisone—ankylosing spondylitis	0.000365	0.00271	CcSEcCtD
Afatinib—BLK—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000364	0.00188	CbGpPWpGaD
Afatinib—Pruritus—Triamcinolone—ankylosing spondylitis	0.000361	0.00268	CcSEcCtD
Afatinib—Cough—Methotrexate—ankylosing spondylitis	0.00036	0.00268	CcSEcCtD
Afatinib—Pruritus—Methylprednisolone—ankylosing spondylitis	0.00036	0.00268	CcSEcCtD
Afatinib—IRAK1—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	0.000359	0.00186	CbGpPWpGaD
Afatinib—Dyspepsia—Prednisone—ankylosing spondylitis	0.000355	0.00264	CcSEcCtD
Afatinib—IRAK1—Immune System—CARD9—ankylosing spondylitis	0.000352	0.00182	CbGpPWpGaD
Afatinib—Decreased appetite—Prednisone—ankylosing spondylitis	0.000351	0.00261	CcSEcCtD
Afatinib—Rash—Prednisolone—ankylosing spondylitis	0.00035	0.0026	CcSEcCtD
Afatinib—Dermatitis—Prednisolone—ankylosing spondylitis	0.00035	0.0026	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000349	0.00259	CcSEcCtD
Afatinib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000348	0.00259	CcSEcCtD
Afatinib—Fatigue—Prednisone—ankylosing spondylitis	0.000348	0.00258	CcSEcCtD
Afatinib—Headache—Prednisolone—ankylosing spondylitis	0.000348	0.00258	CcSEcCtD
Afatinib—Constipation—Prednisone—ankylosing spondylitis	0.000345	0.00256	CcSEcCtD
Afatinib—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000344	0.00178	CbGpPWpGaD
Afatinib—Dizziness—Triamcinolone—ankylosing spondylitis	0.000338	0.00251	CcSEcCtD
Afatinib—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000337	0.0025	CcSEcCtD
Afatinib—Infection—Methotrexate—ankylosing spondylitis	0.000335	0.00249	CcSEcCtD
Afatinib—Asthenia—Betamethasone—ankylosing spondylitis	0.000332	0.00247	CcSEcCtD
Afatinib—Asthenia—Dexamethasone—ankylosing spondylitis	0.000332	0.00247	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000331	0.00246	CcSEcCtD
Afatinib—Nausea—Prednisolone—ankylosing spondylitis	0.00033	0.00245	CcSEcCtD
Afatinib—Pruritus—Betamethasone—ankylosing spondylitis	0.000328	0.00243	CcSEcCtD
Afatinib—Pruritus—Dexamethasone—ankylosing spondylitis	0.000328	0.00243	CcSEcCtD
Afatinib—Skin disorder—Methotrexate—ankylosing spondylitis	0.000327	0.00243	CcSEcCtD
Afatinib—Vomiting—Triamcinolone—ankylosing spondylitis	0.000325	0.00241	CcSEcCtD
Afatinib—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000324	0.00241	CcSEcCtD
Afatinib—Rash—Triamcinolone—ankylosing spondylitis	0.000322	0.00239	CcSEcCtD
Afatinib—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000322	0.00239	CcSEcCtD
Afatinib—Rash—Methylprednisolone—ankylosing spondylitis	0.000321	0.00239	CcSEcCtD
Afatinib—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000321	0.00238	CcSEcCtD
Afatinib—Headache—Triamcinolone—ankylosing spondylitis	0.00032	0.00238	CcSEcCtD
Afatinib—Headache—Methylprednisolone—ankylosing spondylitis	0.000319	0.00237	CcSEcCtD
Afatinib—Body temperature increased—Prednisone—ankylosing spondylitis	0.000319	0.00237	CcSEcCtD
Afatinib—ABL1—Immune System—IL1R2—ankylosing spondylitis	0.000318	0.00164	CbGpPWpGaD
Afatinib—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000317	0.00235	CcSEcCtD
Afatinib—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000317	0.00235	CcSEcCtD
Afatinib—EGFR—Disease—ANTXR2—ankylosing spondylitis	0.000314	0.00162	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000313	0.00162	CbGpPWpGaD
Afatinib—PHKG2—Disease—HLA-A—ankylosing spondylitis	0.000312	0.00161	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—HLA-B—ankylosing spondylitis	0.00031	0.00161	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000309	0.0016	CbGpPWpGaD
Afatinib—Dizziness—Dexamethasone—ankylosing spondylitis	0.000306	0.00228	CcSEcCtD
Afatinib—Dizziness—Betamethasone—ankylosing spondylitis	0.000306	0.00228	CcSEcCtD
Afatinib—ERBB4—Innate Immune System—HLA-B—ankylosing spondylitis	0.000306	0.00158	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HLA-C—ankylosing spondylitis	0.000306	0.00158	CbGpPWpGaD
Afatinib—Insomnia—Methotrexate—ankylosing spondylitis	0.000305	0.00227	CcSEcCtD
Afatinib—Nausea—Triamcinolone—ankylosing spondylitis	0.000303	0.00225	CcSEcCtD
Afatinib—Nausea—Methylprednisolone—ankylosing spondylitis	0.000302	0.00225	CcSEcCtD
Afatinib—LCK—Disease—ANTXR2—ankylosing spondylitis	0.000302	0.00156	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HLA-C—ankylosing spondylitis	0.000301	0.00156	CbGpPWpGaD
Afatinib—ABL1—Immune System—ERAP1—ankylosing spondylitis	0.000301	0.00156	CbGpPWpGaD
Afatinib—ERBB2—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000301	0.00156	CbGpPWpGaD
Afatinib—Dyspnoea—Methotrexate—ankylosing spondylitis	0.0003	0.00223	CcSEcCtD
Afatinib—ERBB2—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000298	0.00154	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000297	0.00154	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000297	0.00154	CbGpPWpGaD
Afatinib—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000297	0.0022	CcSEcCtD
Afatinib—Vomiting—Dexamethasone—ankylosing spondylitis	0.000294	0.00219	CcSEcCtD
Afatinib—Vomiting—Betamethasone—ankylosing spondylitis	0.000294	0.00219	CcSEcCtD
Afatinib—LCK—HIV Infection—HLA-A—ankylosing spondylitis	0.000294	0.00152	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000294	0.00152	CbGpPWpGaD
Afatinib—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000293	0.00218	CcSEcCtD
Afatinib—Rash—Betamethasone—ankylosing spondylitis	0.000292	0.00217	CcSEcCtD
Afatinib—Rash—Dexamethasone—ankylosing spondylitis	0.000292	0.00217	CcSEcCtD
Afatinib—Dermatitis—Betamethasone—ankylosing spondylitis	0.000292	0.00217	CcSEcCtD
Afatinib—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000292	0.00217	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000291	0.00216	CcSEcCtD
Afatinib—Fatigue—Methotrexate—ankylosing spondylitis	0.000291	0.00216	CcSEcCtD
Afatinib—Headache—Dexamethasone—ankylosing spondylitis	0.00029	0.00216	CcSEcCtD
Afatinib—Headache—Betamethasone—ankylosing spondylitis	0.00029	0.00216	CcSEcCtD
Afatinib—BLK—Immune System—HLA-C—ankylosing spondylitis	0.00029	0.0015	CbGpPWpGaD
Afatinib—Asthenia—Prednisone—ankylosing spondylitis	0.000289	0.00215	CcSEcCtD
Afatinib—Pruritus—Prednisone—ankylosing spondylitis	0.000285	0.00212	CcSEcCtD
Afatinib—BLK—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000282	0.00146	CbGpPWpGaD
Afatinib—IRAK1—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	0.00028	0.00145	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000276	0.00143	CbGpPWpGaD
Afatinib—Diarrhoea—Prednisone—ankylosing spondylitis	0.000276	0.00205	CcSEcCtD
Afatinib—ABL1—Immune System—CARD9—ankylosing spondylitis	0.000275	0.00142	CbGpPWpGaD
Afatinib—Nausea—Betamethasone—ankylosing spondylitis	0.000275	0.00204	CcSEcCtD
Afatinib—Nausea—Dexamethasone—ankylosing spondylitis	0.000275	0.00204	CcSEcCtD
Afatinib—ERBB2—Innate Immune System—CRP—ankylosing spondylitis	0.000274	0.00142	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000273	0.00141	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000272	0.00141	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1R2—ankylosing spondylitis	0.000271	0.0014	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—CRP—ankylosing spondylitis	0.00027	0.0014	CbGpPWpGaD
Afatinib—Dizziness—Prednisone—ankylosing spondylitis	0.000267	0.00198	CcSEcCtD
Afatinib—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000266	0.00198	CcSEcCtD
Afatinib—ERBB2—Immune System—IL1RN—ankylosing spondylitis	0.000266	0.00137	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—TLR4—ankylosing spondylitis	0.000263	0.00136	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000262	0.00135	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL1RN—ankylosing spondylitis	0.000262	0.00135	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1R2—ankylosing spondylitis	0.000262	0.00135	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—TLR4—ankylosing spondylitis	0.000259	0.00134	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000258	0.00133	CbGpPWpGaD
Afatinib—EGFR—Immune System—ERAP1—ankylosing spondylitis	0.000257	0.00133	CbGpPWpGaD
Afatinib—Vomiting—Prednisone—ankylosing spondylitis	0.000256	0.00191	CcSEcCtD
Afatinib—Rash—Prednisone—ankylosing spondylitis	0.000254	0.00189	CcSEcCtD
Afatinib—Dermatitis—Prednisone—ankylosing spondylitis	0.000254	0.00189	CcSEcCtD
Afatinib—EGFR—Innate Immune System—HLA-C—ankylosing spondylitis	0.000254	0.00131	CbGpPWpGaD
Afatinib—Headache—Prednisone—ankylosing spondylitis	0.000253	0.00188	CcSEcCtD
Afatinib—BLK—Immune System—IL1RN—ankylosing spondylitis	0.000252	0.0013	CbGpPWpGaD
Afatinib—LCK—Immune System—ERAP1—ankylosing spondylitis	0.000248	0.00128	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HLA-C—ankylosing spondylitis	0.000245	0.00126	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000244	0.00126	CbGpPWpGaD
Afatinib—Asthenia—Methotrexate—ankylosing spondylitis	0.000242	0.0018	CcSEcCtD
Afatinib—Nausea—Prednisone—ankylosing spondylitis	0.00024	0.00178	CcSEcCtD
Afatinib—LCK—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000239	0.00124	CbGpPWpGaD
Afatinib—Pruritus—Methotrexate—ankylosing spondylitis	0.000238	0.00177	CcSEcCtD
Afatinib—EGFR—Immune System—CARD9—ankylosing spondylitis	0.000235	0.00122	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000235	0.00121	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD79A—ankylosing spondylitis	0.000233	0.00121	CbGpPWpGaD
Afatinib—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000231	0.00171	CcSEcCtD
Afatinib—ERBB4—Immune System—CD79A—ankylosing spondylitis	0.00023	0.00119	CbGpPWpGaD
Afatinib—LCK—Immune System—CARD9—ankylosing spondylitis	0.000227	0.00117	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000224	0.00116	CbGpPWpGaD
Afatinib—Dizziness—Methotrexate—ankylosing spondylitis	0.000223	0.00166	CcSEcCtD
Afatinib—IRAK1—Immune System—HLA-C—ankylosing spondylitis	0.000221	0.00114	CbGpPWpGaD
Afatinib—BLK—Immune System—CD79A—ankylosing spondylitis	0.000221	0.00114	CbGpPWpGaD
Afatinib—Vomiting—Methotrexate—ankylosing spondylitis	0.000214	0.00159	CcSEcCtD
Afatinib—EGFR—Spinal Cord Injury—TNF—ankylosing spondylitis	0.000214	0.00111	CbGpPWpGaD
Afatinib—Rash—Methotrexate—ankylosing spondylitis	0.000213	0.00158	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—ankylosing spondylitis	0.000212	0.00158	CcSEcCtD
Afatinib—Headache—Methotrexate—ankylosing spondylitis	0.000211	0.00157	CcSEcCtD
Afatinib—Nausea—Methotrexate—ankylosing spondylitis	0.0002	0.00149	CcSEcCtD
Afatinib—IRAK1—Innate Immune System—CRP—ankylosing spondylitis	0.000198	0.00103	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL1RN—ankylosing spondylitis	0.000192	0.000993	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL1A—ankylosing spondylitis	0.000191	0.000989	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—TLR4—ankylosing spondylitis	0.00019	0.000983	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD40LG—ankylosing spondylitis	0.00019	0.000983	CbGpPWpGaD
Afatinib—EPHA6—Developmental Biology—TNF—ankylosing spondylitis	0.00019	0.000983	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL1A—ankylosing spondylitis	0.000188	0.000974	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD40LG—ankylosing spondylitis	0.000187	0.000968	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000186	0.000961	CbGpPWpGaD
Afatinib—EGFR—Disease—B3GNT2—ankylosing spondylitis	0.000185	0.000956	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000184	0.000949	CbGpPWpGaD
Afatinib—BLK—Immune System—IL1A—ankylosing spondylitis	0.000181	0.000937	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000181	0.000935	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HLA-B—ankylosing spondylitis	0.000181	0.000935	CbGpPWpGaD
Afatinib—BLK—Immune System—CD40LG—ankylosing spondylitis	0.00018	0.000931	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000179	0.000926	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HLA-B—ankylosing spondylitis	0.000178	0.000921	CbGpPWpGaD
Afatinib—LCK—Disease—B3GNT2—ankylosing spondylitis	0.000178	0.000921	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000176	0.000908	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-C—ankylosing spondylitis	0.000173	0.000894	CbGpPWpGaD
Afatinib—BLK—Immune System—HLA-B—ankylosing spondylitis	0.000171	0.000886	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.00017	0.00088	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD79A—ankylosing spondylitis	0.000169	0.000872	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HLA-A—ankylosing spondylitis	0.000168	0.000866	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HLA-A—ankylosing spondylitis	0.000165	0.000853	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000161	0.000833	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CRP—ankylosing spondylitis	0.00016	0.000826	CbGpPWpGaD
Afatinib—BLK—Immune System—HLA-A—ankylosing spondylitis	0.000159	0.000821	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CRP—ankylosing spondylitis	0.000157	0.000814	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CRP—ankylosing spondylitis	0.000155	0.000803	CbGpPWpGaD
Afatinib—ERBB2—Disease—HLA-A—ankylosing spondylitis	0.000155	0.0008	CbGpPWpGaD
Afatinib—ERBB2—Immune System—TLR4—ankylosing spondylitis	0.000153	0.000792	CbGpPWpGaD
Afatinib—ERBB4—Disease—HLA-A—ankylosing spondylitis	0.000152	0.000788	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000152	0.000783	CbGpPWpGaD
Afatinib—BLK—Immune System—CRP—ankylosing spondylitis	0.000151	0.000783	CbGpPWpGaD
Afatinib—ERBB4—Immune System—TLR4—ankylosing spondylitis	0.000151	0.00078	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL1RN—ankylosing spondylitis	0.00015	0.000777	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.00015	0.000777	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HLA-B—ankylosing spondylitis	0.00015	0.000776	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—TLR4—ankylosing spondylitis	0.000149	0.00077	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	0.000149	0.000769	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-C—ankylosing spondylitis	0.000148	0.000764	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000146	0.000755	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000145	0.000752	CbGpPWpGaD
Afatinib—BLK—Immune System—TLR4—ankylosing spondylitis	0.000145	0.000751	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HLA-B—ankylosing spondylitis	0.000145	0.000748	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—B3GNT2—ankylosing spondylitis	0.000144	0.000747	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000144	0.000745	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-C—ankylosing spondylitis	0.000142	0.000737	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—TNF—ankylosing spondylitis	0.000141	0.000727	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000139	0.000718	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL1A—ankylosing spondylitis	0.000138	0.000715	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD40LG—ankylosing spondylitis	0.000137	0.000711	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000134	0.00069	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000133	0.000686	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CRP—ankylosing spondylitis	0.000133	0.000686	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD79A—ankylosing spondylitis	0.000132	0.000682	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HLA-B—ankylosing spondylitis	0.000131	0.000676	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MMP3—ankylosing spondylitis	0.000131	0.000676	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MMP3—ankylosing spondylitis	0.000129	0.000666	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000129	0.000665	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1RN—ankylosing spondylitis	0.000128	0.000664	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CRP—ankylosing spondylitis	0.000128	0.000661	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—TLR4—ankylosing spondylitis	0.000127	0.000658	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1RN—ankylosing spondylitis	0.000124	0.00064	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—TLR4—ankylosing spondylitis	0.000123	0.000634	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HLA-A—ankylosing spondylitis	0.000121	0.000626	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CRP—ankylosing spondylitis	0.000116	0.000597	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD79A—ankylosing spondylitis	0.000113	0.000583	CbGpPWpGaD
Afatinib—IRAK1—Immune System—TLR4—ankylosing spondylitis	0.000111	0.000573	CbGpPWpGaD
Afatinib—LCK—Immune System—CD79A—ankylosing spondylitis	0.000109	0.000562	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL1A—ankylosing spondylitis	0.000108	0.000559	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD40LG—ankylosing spondylitis	0.000108	0.000556	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000107	0.000553	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-B—ankylosing spondylitis	0.000102	0.000529	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-A—ankylosing spondylitis	9.48e-05	0.00049	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP3—ankylosing spondylitis	9.45e-05	0.000489	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1A—ankylosing spondylitis	9.24e-05	0.000478	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD40LG—ankylosing spondylitis	9.19e-05	0.000475	CbGpPWpGaD
Afatinib—ABL1—Immune System—CRP—ankylosing spondylitis	9.04e-05	0.000468	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1A—ankylosing spondylitis	8.91e-05	0.000461	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTGER4—ankylosing spondylitis	8.88e-05	0.000459	CbGpPWpGaD
Afatinib—LCK—Immune System—CD40LG—ankylosing spondylitis	8.86e-05	0.000458	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-B—ankylosing spondylitis	8.74e-05	0.000452	CbGpPWpGaD
Afatinib—ABL1—Immune System—TLR4—ankylosing spondylitis	8.67e-05	0.000448	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTGER4—ankylosing spondylitis	8.55e-05	0.000442	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-B—ankylosing spondylitis	8.42e-05	0.000436	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-A—ankylosing spondylitis	8.1e-05	0.000419	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TNF—ankylosing spondylitis	7.96e-05	0.000411	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	7.81e-05	0.000404	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-A—ankylosing spondylitis	7.8e-05	0.000404	CbGpPWpGaD
Afatinib—EGFR—Immune System—CRP—ankylosing spondylitis	7.73e-05	0.0004	CbGpPWpGaD
Afatinib—EGFR—Disease—HLA-A—ankylosing spondylitis	7.48e-05	0.000387	CbGpPWpGaD
Afatinib—LCK—Immune System—CRP—ankylosing spondylitis	7.45e-05	0.000385	CbGpPWpGaD
Afatinib—EGFR—Immune System—TLR4—ankylosing spondylitis	7.41e-05	0.000383	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	7.34e-05	0.00038	CbGpPWpGaD
Afatinib—LCK—Disease—HLA-A—ankylosing spondylitis	7.21e-05	0.000373	CbGpPWpGaD
Afatinib—LCK—Immune System—TLR4—ankylosing spondylitis	7.14e-05	0.000369	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TNF—ankylosing spondylitis	6.8e-05	0.000352	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP3—ankylosing spondylitis	6.32e-05	0.000327	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP3—ankylosing spondylitis	6.09e-05	0.000315	CbGpPWpGaD
